Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDADiscover the Best Stocks and Maximize Your Portfolio: See ...

The announcement came after a quarter where DexCom reported a 7% increase in sales, though net income declined significantly alongside a reduction in earnings per share. During the past quarter ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

In a report released yesterday, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7 ...